➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Dow
Mallinckrodt
Colorcon
Boehringer Ingelheim

Last Updated: June 23, 2021

DrugPatentWatch Database Preview

OFIRMEV Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Ofirmev patents expire, and what generic alternatives are available?

Ofirmev is a drug marketed by Mallinckrodt Hosp and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has nineteen patent family members in sixteen countries.

The generic ingredient in OFIRMEV is acetaminophen. There are sixty-six drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the acetaminophen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ofirmev

A generic version of OFIRMEV was approved as acetaminophen by PERRIGO on February 25th, 2000.

  Get Started Free

Drug patent expirations by year for OFIRMEV
Drug Prices for OFIRMEV

See drug prices for OFIRMEV

Recent Clinical Trials for OFIRMEV

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Nevakar, IncPhase 2
Lotus Clinical Research, LLCPhase 2
Lotus Clinical Research, LLCPhase 1

See all OFIRMEV clinical trials

Paragraph IV (Patent) Challenges for OFIRMEV
Tradename Dosage Ingredient NDA Submissiondate
OFIRMEV SOLUTION;INTRAVENOUS acetaminophen 022450 2011-04-07

US Patents and Regulatory Information for OFIRMEV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Hosp OFIRMEV acetaminophen SOLUTION;INTRAVENOUS 022450-001 Nov 2, 2010 AP RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Mallinckrodt Hosp OFIRMEV acetaminophen SOLUTION;INTRAVENOUS 022450-001 Nov 2, 2010 AP RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Mallinckrodt Hosp OFIRMEV acetaminophen SOLUTION;INTRAVENOUS 022450-001 Nov 2, 2010 AP RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Mallinckrodt Hosp OFIRMEV acetaminophen SOLUTION;INTRAVENOUS 022450-001 Nov 2, 2010 AP RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Mallinckrodt Hosp OFIRMEV acetaminophen SOLUTION;INTRAVENOUS 022450-001 Nov 2, 2010 AP RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
AstraZeneca
Mallinckrodt
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.